We found that treatment of MCF-7/ER(D538G) cells with the anti-MUC1-C ADC also suppresses self-renewal capacity, indicating that this agent is a potential candidate for patients with HR+/HER2− BC harboring the highly prevalent ER(Y537S) and ER(D538G) mutations. This evidence concerns the gene HR and breast cancer.